{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:58:55Z","timestamp":1791305935508,"version":"4.3.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,1,10]],"date-time":"2012-01-10T00:00:00Z","timestamp":1326153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2012,1,10]],"date-time":"2012-01-10T00:00:00Z","timestamp":1326153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/ncomms1623","type":"journal-article","created":{"date-parts":[[2012,1,10]],"date-time":"2012-01-10T09:34:46Z","timestamp":1326188086000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease"],"prefix":"10.1038","volume":"3","author":[{"given":"A.","family":"Herrera-Merchan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Arranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Ligos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"de Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,1,10]]},"reference":[{"key":"BFncomms1623_CR1","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.gde.2006.08.011","volume":"16","author":"OO Akala","year":"2006","unstructured":"Akala, O. O. & Clarke, M. F. Hematopoietic stem cell self-renewal. Curr. Opin. Genet. Dev. 16, 496\u2013501 (2006).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"BFncomms1623_CR2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/nrc2736","volume":"9","author":"AP Bracken","year":"2009","unstructured":"Bracken, A. P. & Helin, K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat. Rev. Cancer 9, 773\u2013784 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"BFncomms1623_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature09784","volume":"469","author":"R Margueron","year":"2011","unstructured":"Margueron, R. & Reinberg, D. The Polycomb complex PRC2 and its mark in life. Nature 469, 343\u2013349 (2011).","journal-title":"Nature"},{"key":"BFncomms1623_CR4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/ng.127","volume":"40","author":"I Ben-Porath","year":"2008","unstructured":"Ben-Porath, I. et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40, 499\u2013507 (2008).","journal-title":"Nat. Genet."},{"key":"BFncomms1623_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/ng1950","volume":"39","author":"Y Schlesinger","year":"2007","unstructured":"Schlesinger, Y. et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 39, 232\u2013236 (2007).","journal-title":"Nat. Genet."},{"key":"BFncomms1623_CR6","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1182\/blood-2010-05-267096","volume":"116","author":"D Martin-Perez","year":"2010","unstructured":"Martin-Perez, D., Piris, M. A. & Sanchez-Beato, M. Polycomb proteins in hematologic malignancies. Blood 116, 5465\u20135475 (2010).","journal-title":"Blood"},{"key":"BFncomms1623_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/ng.518","volume":"42","author":"RD Morin","year":"2010","unstructured":"Morin, R. D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181\u2013185 (2010).","journal-title":"Nat. Genet."},{"key":"BFncomms1623_CR8","doi-asserted-by":"publisher","first-page":"20980","DOI":"10.1073\/pnas.1012525107","volume":"107","author":"CJ Sneeringer","year":"2011","unstructured":"Sneeringer, C. J. et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl Acad. Sci. U S A 107, 20980\u201320985 (2011).","journal-title":"Proc. Natl Acad. Sci. U S A"},{"key":"BFncomms1623_CR9","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1182\/blood-2010-11-321208","volume":"117","author":"DB Yap","year":"2010","unstructured":"Yap, D. B. et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117, 2451\u20132459 (2010).","journal-title":"Blood"},{"key":"BFncomms1623_CR10","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00277-010-1128-5","volume":"90","author":"F Xu","year":"2010","unstructured":"Xu, F. et al. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring. Ann. Hematol. 90, 643\u2013653 (2010).","journal-title":"Ann. Hematol."},{"key":"BFncomms1623_CR11","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1182\/blood-2009-07-233858","volume":"115","author":"TA Paul","year":"2010","unstructured":"Paul, T. A. et al. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML. Blood 115, 3098\u20133108 (2010).","journal-title":"Blood"},{"key":"BFncomms1623_CR12","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1182\/blood-2009-03-213496","volume":"114","author":"W Fiskus","year":"2009","unstructured":"Fiskus, W. et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114, 2733\u20132743 (2009).","journal-title":"Blood"},{"key":"BFncomms1623_CR13","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/ng.620","volume":"42","author":"G Nikoloski","year":"2010","unstructured":"Nikoloski, G. et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 42, 665\u2013667 (2010).","journal-title":"Nat. Genet."},{"key":"BFncomms1623_CR14","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/ng.621","volume":"42","author":"T Ernst","year":"2010","unstructured":"Ernst, T. et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 42, 722\u2013726 (2010).","journal-title":"Nat. Genet."},{"key":"BFncomms1623_CR15","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/immu.200310005","volume":"33","author":"J de Boer","year":"2003","unstructured":"de Boer, J. et al. Transgenic mice with hematopoietic and lymphoid specific expression of Cre. Eur. J. Immunol. 33, 314\u2013325 (2003).","journal-title":"Eur. J. Immunol."},{"key":"BFncomms1623_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1074-7613(04)00022-6","volume":"20","author":"BA Croker","year":"2004","unstructured":"Croker, B. A. et al. SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity 20, 153\u2013165 (2004).","journal-title":"Immunity"},{"key":"BFncomms1623_CR17","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.V94.6.1855","volume":"94","author":"S Ogilvy","year":"1999","unstructured":"Ogilvy, S. et al. Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment. Blood 94, 1855\u20131863 (1999).","journal-title":"Blood"},{"key":"BFncomms1623_CR18","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1084\/jem.183.4.1797","volume":"183","author":"MA Goodell","year":"1996","unstructured":"Goodell, M. A. et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 183, 1797\u20131806 (1996).","journal-title":"J. Exp. Med."},{"key":"BFncomms1623_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nature05541","volume":"445","author":"A Ventura","year":"2007","unstructured":"Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661\u2013665 (2007).","journal-title":"Nature"},{"key":"BFncomms1623_CR20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1023\/A:1008942828960","volume":"8","author":"BE Clausen","year":"1999","unstructured":"Clausen, B. E. et al. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8, 265\u2013277 (1999).","journal-title":"Transgenic Res."},{"key":"BFncomms1623_CR21","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1084\/jem.20050967","volume":"202","author":"E Passegue","year":"2005","unstructured":"Passegue, E. et al. Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J. Exp. Med. 202, 1599\u20131611 (2005).","journal-title":"J. Exp. Med."},{"key":"BFncomms1623_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner, M. et al. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat. Genet. 25, 25\u201329 (2000).","journal-title":"Nat. Genet."},{"key":"BFncomms1623_CR23","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.stem.2007.06.001","volume":"1","author":"MJ Kiel","year":"2007","unstructured":"Kiel, M. J., Radice, G. L. & Morrison, S. J. Lack of evidence that hematopoietic stem cells depend on N-cadherin-mediated adhesion to osteoblasts for their maintenance. Cell Stem Cell 1, 204\u2013217 (2007).","journal-title":"Cell Stem Cell"},{"key":"BFncomms1623_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cell.2004.07.004","volume":"118","author":"F Arai","year":"2004","unstructured":"Arai, F. et al. Tie2\/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 118, 149\u2013161 (2004).","journal-title":"Cell"},{"key":"BFncomms1623_CR25","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1182\/blood-2007-07-103010","volume":"112","author":"WF Tam","year":"2008","unstructured":"Tam, W. F. et al. Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. Blood 112, 1981\u20131992 (2008).","journal-title":"Blood"},{"key":"BFncomms1623_CR26","doi-asserted-by":"publisher","first-page":"e8785","DOI":"10.1371\/journal.pone.0008785","volume":"5","author":"EC Forsberg","year":"2010","unstructured":"Forsberg, E. C. et al. Molecular signatures of quiescent, mobilized and leukemia-initiating hematopoietic stem cells. PLoS One 5, e8785 (2010).","journal-title":"PLoS One"},{"key":"BFncomms1623_CR27","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1172\/JCI21716","volume":"114","author":"S Buonamici","year":"2004","unstructured":"Buonamici, S. et al. EVI1 induces myelodysplastic syndrome in mice. J. Clin. Invest. 114, 713\u2013719 (2004).","journal-title":"J. Clin. Invest."},{"key":"BFncomms1623_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.stem.2008.06.002","volume":"3","author":"S Goyama","year":"2008","unstructured":"Goyama, S. et al. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 3, 207\u2013220 (2008).","journal-title":"Cell Stem Cell"},{"key":"BFncomms1623_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/leu.2009.202","volume":"24","author":"S Goyama","year":"2010","unstructured":"Goyama, S. et al. EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization. Leukemia 24, 81\u201388 (2010).","journal-title":"Leukemia"},{"key":"BFncomms1623_CR30","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1101\/gad.415507","volume":"21","author":"AP Bracken","year":"2007","unstructured":"Bracken, A. P. et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 21, 525\u2013530 (2007).","journal-title":"Genes Dev."},{"key":"BFncomms1623_CR31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.stem.2010.08.002","volume":"7","author":"M Sauvageau","year":"2010","unstructured":"Sauvageau, M. & Sauvageau, G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 7, 299\u2013313 (2010).","journal-title":"Cell Stem Cell"},{"key":"BFncomms1623_CR32","doi-asserted-by":"publisher","first-page":"550","DOI":"10.4161\/cc.6.5.3919","volume":"6","author":"A Tefferi","year":"2007","unstructured":"Tefferi, A. & Gilliland, D. G. Oncogenes in myeloproliferative disorders. Cell Cycle 6, 550\u2013566 (2007).","journal-title":"Cell Cycle"},{"key":"BFncomms1623_CR33","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/blood.V100.1.238","volume":"100","author":"SC Kogan","year":"2002","unstructured":"Kogan, S. C. et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood 100, 238\u2013245 (2002).","journal-title":"Blood"},{"key":"BFncomms1623_CR34","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nature04431","volume":"439","author":"E Vire","year":"2006","unstructured":"Vire, E. et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439, 871\u2013874 (2006).","journal-title":"Nature"},{"key":"BFncomms1623_CR35","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/ng1972","volume":"39","author":"JE Ohm","year":"2007","unstructured":"Ohm, J. E. et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet. 39, 237\u2013242 (2007).","journal-title":"Nat. Genet."},{"key":"BFncomms1623_CR36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/ng1941","volume":"39","author":"M Widschwendter","year":"2007","unstructured":"Widschwendter, M. et al. Epigenetic stem cell signature in cancer. Nat. Genet. 39, 157\u2013158 (2007).","journal-title":"Nat. Genet."},{"key":"BFncomms1623_CR37","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860\u2013867 (2002).","journal-title":"Nature"},{"key":"BFncomms1623_CR38","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","volume":"128","author":"PA Jones","year":"2007","unstructured":"Jones, P. A. & Baylin, S. B. The epigenomics of cancer. Cell 128, 683\u2013692 (2007).","journal-title":"Cell"},{"key":"BFncomms1623_CR39","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","volume":"364","author":"R Bejar","year":"2011","unstructured":"Bejar, R. et al. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 364, 2496\u20132506 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFncomms1623_CR40","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ceb.2004.03.010","volume":"16","author":"AH Lund","year":"2004","unstructured":"Lund, A. H. & van Lohuizen, M. Polycomb complexes and silencing mechanisms. Curr. Opin. Cell Biol. 16, 239\u2013246 (2004).","journal-title":"Curr. Opin. Cell Biol."},{"key":"BFncomms1623_CR41","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.devcel.2006.03.002","volume":"10","author":"E Passegue","year":"2006","unstructured":"Passegue, E. & Wagers, A. J. Regulating quiescence: new insights into hematopoietic stem cell biology. Dev. Cell 10, 415\u2013417 (2006).","journal-title":"Dev. Cell"},{"key":"BFncomms1623_CR42","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1182\/blood-2010-04-280750","volume":"117","author":"Q Li","year":"2011","unstructured":"Li, Q. et al. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood 117, 2022\u20132032 (2011).","journal-title":"Blood"},{"key":"BFncomms1623_CR43","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.beha.2009.08.005","volume":"22","author":"ML Cleary","year":"2009","unstructured":"Cleary, M. L. Regulating the leukaemia stem cell. Best Pract. Res. Clin. Haematol. 22, 483\u2013487 (2009).","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"BFncomms1623_CR44","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1073\/pnas.0307203101","volume":"101","author":"BS Braun","year":"2004","unstructured":"Braun, B. S. et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc. Natl Acad. Sci. U S A 101, 597\u2013602 (2004).","journal-title":"Proc. Natl Acad. Sci. U S A"},{"key":"BFncomms1623_CR45","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","volume":"17","author":"A Mullally","year":"2010","unstructured":"Mullally, A. et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 17, 584\u2013596 (2010).","journal-title":"Cancer Cell"},{"key":"BFncomms1623_CR46","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/wsbm.145","volume":"3","author":"MR Warr","year":"2011","unstructured":"Warr, M. R., Pietras, E. M. & Passegue, E. Mechanisms controlling hematopoietic stem cell functions during normal hematopoiesis and hematological malignancies. Wiley Interdiscip. Rev. Syst. Biol. Med. 3, 681\u2013701 (2011).","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"BFncomms1623_CR47","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.4161\/cc.9.16.12598","volume":"9","author":"A Herrera-Merchan","year":"2010","unstructured":"Herrera-Merchan, A. et al. miR-33-mediated downregulation of p53 controls hematopoietic stem cell self-renewal. Cell Cycle 9, 3277\u20133285 (2010).","journal-title":"Cell Cycle"},{"key":"BFncomms1623_CR48","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.4161\/cc.7.16.6541","volume":"7","author":"S Gonzalez","year":"2008","unstructured":"Gonzalez, S., Pisano, D. G. & Serrano, M. Mechanistic principles of chromatin remodeling guided by siRNAs and miRNAs. Cell Cycle 7, 2601\u20132608 (2008).","journal-title":"Cell Cycle"},{"key":"BFncomms1623_CR49","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nature04585","volume":"440","author":"S Gonzalez","year":"2006","unstructured":"Gonzalez, S. et al. Oncogenic activity of Cdc6 through repression of the INK4\/ARF locus. Nature 440, 702\u2013706 (2006).","journal-title":"Nature"}],"updated-by":[{"DOI":"10.1038\/ncomms14005","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T00:00:00Z","timestamp":1488844800000},"record-id":"5158"},{"DOI":"10.1038\/ncomms14005","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T00:00:00Z","timestamp":1488844800000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ncomms1623","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms1623.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms1623.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:48:51Z","timestamp":1672966131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncomms1623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,10]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,1]]}},"alternative-id":["BFncomms1623"],"URL":"https:\/\/doi.org\/10.1038\/ncomms1623","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,10]]},"assertion":[{"value":"18 October 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2017","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This paper has been retracted at the request of the authors.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"623"}}